F-star lines up Takeda pact weeks after M&A exit; En route to Europe decision, GenSight touts 5-year data
Weeks after wrapping up a monthslong search for a new owner, F-star Therapeutics has signed a licensing agreement with Takeda for a new immuno-oncology bispecific antibody.
The deal terms are far from the big figures floated by other Big Pharma-biotech tie-ups in recent months, with Takeda doling out $1 million to start and offering up to $40 million more in back-end payments if all milestones are met, the companies said Wednesday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.